Piperidine derivatives having anxiolytic effect
AssigneeH. Lundbeck A/S
InventorsEjner K. Moltzen, Jens Kristian Perregaard
Life of this patent
Estimating the term…
Loading patent…
AssigneeH. Lundbeck A/S
InventorsEjner K. Moltzen, Jens Kristian Perregaard
Estimating the term…
Piperidine compounds having the general formula (I), wherein R1 is (a) a group consisting of alkyl, alkenyl, cycloalkyl, cycloalkenyl, phenyl, cycloalkylalkyl, cycloalkenylalkyl, phenylalkyl or diphenylalkyl linked to the piperidyl N-atom through an at least 2-membered spacer group; or (b) a group having general formula (II), wherein X is CHR10, O, S, SO, SO2 or NR10, Z1 is CH2, O, or S; Z2 and Z3 are independently (CH2)n, n being 0 or 1, O or S or Z1 and Z2 may together represent a group —CH═CH—; or when Z3 is (CH2)n wherein n is 0, Z1 and Z2 may together represent a 3-membered divalent group; show potent sigma receptor activity. Furthermore they show effect in animal models indicative of anxiolytic properties. Accordingly they are useful as medicines for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile demential of the Alzheimer type or Parkinson's disease.
A method for treating anxiety, epilepsy, convulsion, movement disorder, or amnesia by action on sigma receptors, comprising adminisering to a patient in need thereof a therapeutically effective amount of a sigma receptor binding compound of formula I:
A method for treating anxiety, psychosis, epilepsy, convulsions, movement disorder, motor disturbance, amnesia, cerebrovascular disease, and senile dementia of Alzheimer's disease, or Parkinson's disease, comprising administering to a patient in need thereof a therapeutically effective amount of a compound having Formula I:
Dependencies are inferred from the claim text.